Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) EBT Margin (2022 - 2025)

Century Therapeutics (IPSC) has disclosed EBT Margin for 4 consecutive years, with 70.13% as the latest value for Q1 2025.

  • On a quarterly basis, EBT Margin rose 335212.0% to 70.13% in Q1 2025 year-over-year; TTM through Sep 2025 was 21.79%, a 484774.0% increase, with the full-year FY2024 number at 1893.7%, up 413726.0% from a year prior.
  • EBT Margin was 70.13% for Q1 2025 at Century Therapeutics, up from 821.85% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 70.13% in Q1 2025 to a low of 32667.68% in Q2 2023.
  • A 4-year average of 7414.95% and a median of 3544.14% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: crashed -3044920bps in 2023, then skyrocketed 2862293bps in 2024.
  • Century Therapeutics' EBT Margin stood at 6074.86% in 2022, then plummeted by -147bps to 15025.0% in 2023, then surged by 95bps to 821.85% in 2024, then skyrocketed by 109bps to 70.13% in 2025.
  • Per Business Quant, the three most recent readings for IPSC's EBT Margin are 70.13% (Q1 2025), 821.85% (Q4 2024), and 3948.67% (Q3 2024).